MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Merck & Co Inc.

Open

SectorGezondheidszorg

79.68 2.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

77.77

Max

79.93

Belangrijke statistieken

By Trading Economics

Inkomsten

583M

3.7B

Verkoop

-1B

16B

K/W

Sectorgemiddelde

11.55

57.333

EPS

1.72

Dividendrendement

4.15

Winstmarge

23.963

Werknemers

73,000

EBITDA

1.3B

6.9B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+35.27% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.15%

2.63%

Volgende dividenddatum

7 jul 2025

Volgende Ex Dividend datum

16 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-56B

196B

Vorige openingsprijs

77.34

Vorige sluitingsprijs

79.68

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Merck & Co Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 apr 2025, 18:18 UTC

Belangrijke Marktbewegers

Pharma Shares Reverse Losses After Tariff Pause

9 apr 2025, 09:39 UTC

Belangrijke Marktbewegers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 feb 2025, 12:33 UTC

Winsten

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 feb 2025, 11:57 UTC

Winsten

Merck 4Q Sales Increase Results in Swing to Profit

24 apr 2025, 20:08 UTC

Winsten

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 apr 2025, 16:05 UTC

Top Nieuws
Winsten

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24 apr 2025, 14:36 UTC

Marktinformatie
Winsten

Merck's Challenges with Gardasil in China Continue -- Market Talk

24 apr 2025, 14:10 UTC

Marktinformatie
Winsten

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24 apr 2025, 11:35 UTC

Winsten

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24 apr 2025, 10:58 UTC

Top Nieuws
Winsten

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24 apr 2025, 10:55 UTC

Winsten

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24 apr 2025, 10:31 UTC

Winsten

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24 apr 2025, 10:30 UTC

Winsten

Merck 1Q Keytruda Sales $7.21B >MRK

24 apr 2025, 10:30 UTC

Winsten

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24 apr 2025, 10:30 UTC

Winsten

Merck 1Q Keytruda Sales Up 4% >MRK

24 apr 2025, 10:30 UTC

Winsten

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24 apr 2025, 10:30 UTC

Winsten

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24 apr 2025, 10:30 UTC

Winsten

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24 apr 2025, 10:30 UTC

Winsten

Merck 1Q Januvia/Janumet Sales $796M >MRK

24 apr 2025, 09:13 UTC

Populaire aandelen

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24 mrt 2025, 05:00 UTC

Winsten
Acquisities, Fusies, Overnames

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mrt 2025, 19:42 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mrt 2025, 10:30 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 feb 2025, 12:00 UTC

Top Nieuws

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 feb 2025, 14:48 UTC

Winsten

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 feb 2025, 11:51 UTC

Winsten

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 feb 2025, 11:50 UTC

Winsten

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 feb 2025, 11:31 UTC

Winsten

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 feb 2025, 11:31 UTC

Winsten

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 feb 2025, 11:31 UTC

Winsten

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Peer Vergelijking

Prijswijziging

Merck & Co Inc. Prognose

Koersdoel

By TipRanks

35.27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 108 USD  35.27%

Hoogste 138 USD

Laagste 85 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck & Co Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

11

Buy

7

Hold

0

Sell

Technische score

By Trading Central

77.85 / 80.02Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.